Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Gains from Investment Securities: 2009-2025

Historic Gains from Investment Securities for BIO-TECHNE (TECH) over the last 17 years, with Jun 2025 value amounting to $9.5 million.

  • BIO-TECHNE's Gains from Investment Securities fell 20.00% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.2 million, marking a year-over-year increase of 179.38%. This contributed to the annual value of $9.5 million for FY2025, which is 18.30% down from last year.
  • BIO-TECHNE's Gains from Investment Securities amounted to $9.5 million in FY2025, which was down 18.30% from $11.6 million recorded in FY2024.
  • In the past 5 years, BIO-TECHNE's Gains from Investment Securities ranged from a high of $14.9 million in FY2021 and a low of $9.5 million during FY2025.
  • Its 3-year average for Gains from Investment Securities is $11.7 million, with a median of $11.6 million in 2024.
  • Per our database at Business Quant, BIO-TECHNE's Gains from Investment Securities spiked by 311.97% in 2021 and then fell by 18.30% in 2025.
  • Over the past 5 years, BIO-TECHNE's Gains from Investment Securities (Yearly) stood at $14.9 million in 2021, then declined by 10.75% to $13.3 million in 2022, then increased by 4.94% to $13.9 million in 2023, then declined by 16.84% to $11.6 million in 2024, then fell by 18.30% to $9.5 million in 2025.